PBA
Paradigm Biocapital Advisors Portfolio holdings
AUM
$2.34B
This Quarter Return
+1.75%
1 Year Return
+13.3%
3 Year Return
+245.82%
5 Year Return
–
10 Year Return
–
AUM
$1.47B
AUM Growth
+$1.47B
(+19%)
Cap. Flow
+$271M
Cap. Flow
% of AUM
18.5%
Top 10 Holdings %
Top 10 Hldgs %
60.98%
Holding
36
New
6
Increased
19
Reduced
3
Closed
6
Top Buys
| 1 |
Disc Medicine
IRON
|
$59.8M |
| 2 |
argenx
ARGX
|
$58.6M |
| 3 |
Olema Pharmaceuticals
OLMA
|
$50.3M |
| 4 |
BCYC
Bicycle Therapeutics
BCYC
|
$33.3M |
| 5 |
TG Therapeutics
TGTX
|
$30.3M |
Top Sells
| 1 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
$61.5M |
| 2 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$38.5M |
| 3 |
Incyte
INCY
|
$27.1M |
| 4 |
Vir Biotechnology
VIR
|
$24.9M |
| 5 |
Madrigal Pharmaceuticals
MDGL
|
$19.6M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Legend Biotech
LEGN
$6.41B
| $136M | 9.23% | 2,025,480 +219,763 | +12% | +$14.8M |
|
|
2
argenx
ARGX
$43.6B
| $129M | 8.72% | 261,443 +119,184 | +84% | +$58.6M |
|
3
Arcellx
ACLX
$3.85B
| $106M | 7.19% | 2,953,122 +606,122 | +26% | +$21.7M |
|
|
4
Olema Pharmaceuticals
OLMA
$375M
| $96.4M | 6.54% | 7,803,600 +4,072,554 | +109% | +$50.3M |
|
5
Nuvalent
NUVL
$5.52B
| $75.3M | 5.11% | 1,638,147 +517,682 | +46% | +$23.8M |
|
|
BCYC
6
Bicycle Therapeutics
BCYC
$511M
| $73.2M | 4.97% | 3,642,307 +1,656,877 | +83% | +$33.3M |
|
|
MRTX
7
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $72.7M | 4.93% | 1,668,116 +224,354 | +16% | +$9.77M |
|
8
Immunocore
IMCR
$1.62B
| $71.9M | 4.88% | 1,384,686 +114,562 | +9% | +$5.95M |
|
9
United Therapeutics
UTHR
$13.8B
| $69.4M | 4.71% | 307,314 +68,926 | +29% | +$15.6M |
|
10
Crinetics Pharmaceuticals
CRNX
$2.92B
| $64.8M | 4.4% | 2,178,737 +783,735 | +56% | +$23.3M |
|
|
11
Disc Medicine
IRON
$2.07B
| $59.8M | 4.06% | +1,272,279 | New | +$59.8M |
|
12
Viridian Therapeutics
VRDN
$1.5B
| $56.5M | 3.83% | 3,681,747 +1,266,491 | +52% | +$19.4M |
|
|
CERE
13
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $55.3M | 3.75% | 2,532,972 +664,026 | +36% | +$14.5M |
|
|
14
Incyte
INCY
$16.5B
| $52.7M | 3.58% | 912,497 -469,214 | -34% | -$27.1M |
|
15
Xenon Pharmaceuticals
XENE
$2.98B
| $51M | 3.46% | 1,491,835 +502,508 | +51% | +$17.2M |
|
|
AMAM
16
DELISTED
Ambrx Biopharma, Inc. Common Stock
AMAM
| $40.1M | 2.72% | 3,488,596 +1,838,097 | +111% | +$21.1M |
|
17
Syndax Pharmaceuticals
SNDX
$1.41B
| $34.7M | 2.36% | 2,390,077 -34,055 | -1% | -$494K |
|
|
AUTL
18
Autolus Therapeutics
AUTL
$399M
| $33.6M | 2.28% | 14,406,782 +5,189,632 | +56% | +$12.1M |
|
|
19
TG Therapeutics
TGTX
$4.65B
| $30.3M | 2.05% | +3,619,015 | New | +$30.3M |
|
20
Zai Lab
ZLAB
$3.68B
| $27.8M | 1.88% | 1,142,383 +277,086 | +32% | +$6.74M |
|
|
ALPN
21
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $27.7M | 1.88% | 2,421,743 -2,218 | -0.1% | -$25.4K |
|
22
Immatics
IMTX
$619M
| $23.8M | 1.62% | 2,058,447 +73,634 | +4% | +$853K |
|
|
VRNA
23
Verona Pharma
VRNA
$9.16B
| $15.1M | 1.02% | 926,432 +32,571 | +4% | +$531K |
|
24
Caribou Biosciences
CRBU
$174M
| $14.1M | 0.96% | +2,944,513 | New | +$14.1M |
|
25
Vor Biopharma
VOR
$250M
| $13.7M | 0.93% | 6,461,467 | – | – |
|